Coherus Biosciences Bundle
What is the history of Coherus BioSciences?
Coherus BioSciences is a commercial-stage biopharmaceutical company focused on oncology and immunology. Its strategy centers on developing and marketing affordable alternatives to established biologic drugs, aiming to increase patient access to vital treatments.
Founded in 2010, Coherus BioSciences began with the goal of enhancing access to essential medicines through biosimilars. The company has evolved significantly, and as of 2025, it is concentrating its efforts on innovative oncology treatments, utilizing its existing commercial infrastructure and pipeline.
The company's journey began in Redwood City, California, with an initial focus on biosimilars. This strategic shift towards innovative oncology demonstrates Coherus's adaptability in the evolving biopharmaceutical sector. For a deeper understanding of its product strategy, consider reviewing the Coherus Biosciences BCG Matrix.
What is the Coherus Biosciences Founding Story?
Coherus BioSciences history began in 2010 when Dennis Lanfear, a seasoned biopharmaceutical executive, founded the company. Doug Treat was also integral to the founding team. Lanfear's vision was to enhance public access to critical medicines, drawing on his extensive experience, including a significant 13-year period at Amgen where he played a role in numerous drug applications.
The Genesis of Coherus Biosciences
Coherus Biosciences was established in 2010 with the primary goal of making high-quality biologic medicines more accessible. The company's founding was driven by the recognition of the significant cost barriers and limited availability of essential biologic treatments.
- Founded in 2010 by Dennis Lanfear, with Doug Treat as a key founding team member.
- Dennis Lanfear brought extensive biopharmaceutical leadership experience, including 13 years at Amgen.
- The company's initial focus was on developing biosimilars to address high drug costs and improve access.
- Secured $55 million in Series A financing in 2011 to support early clinical development programs.
The core of Coherus Biosciences' early strategy was to develop biosimilars, which are highly similar, cost-effective alternatives to existing branded biologic drugs. This approach was strategically chosen in response to the increasing demand for affordable healthcare and the upcoming patent expirations of several major biologic medications, creating an opportunity to impact the Target Market of Coherus Biosciences.
Coherus Biosciences SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of Coherus Biosciences?
Coherus BioSciences began its journey by concentrating on the meticulous development of biosimilar candidates. The company's early growth was marked by strategic filings and clinical trials, setting the stage for its future commercial endeavors in the biosimilar market.
Early Biosimilar Development and Global Expansion
The Coherus Biosciences history includes a significant early milestone in 2012 with the filing of its first biosimilar application in Europe. This was followed by the initiation of a global Phase 3 clinical trial for its lead biosimilar candidate in 2014, underscoring a commitment to robust clinical validation.
Transition to Commercialization with UDENYCA Approval
A pivotal moment in the Coherus Biosciences evolution was the 2017 FDA approval of UDENYCA (pegfilgrastim-cbqv). This marked the company's transition from a development-stage entity to a commercial one, with the product officially launching in the U.S. on January 3, 2019.
Strategic Acquisitions and Portfolio Expansion
Coherus Biosciences expanded its ophthalmology and oncology portfolios through strategic acquisitions. In November 2019, the company secured U.S. commercial rights for a Lucentis biosimilar candidate, and in January 2020, it acquired U.S. commercial rights for an Avastin biosimilar.
Key Product Launches and Market Penetration
The company achieved FDA approval for CIMERLI (ranibizumab-eqrn), an interchangeable biosimilar to Lucentis, in 2022, launching commercially at a 30% discount. By August 2023, CIMERLI captured a 25% market share. In July 2023, Coherus launched YUSIMRY (adalimumab-aqvh), a biosimilar of Humira, at a list price representing over an 85% discount. These launches significantly boosted net revenue to $257.2 million in 2023, a substantial increase from $21.0 million in 2022, showcasing the Brief History of Coherus Biosciences and its impact.
Coherus Biosciences PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in Coherus Biosciences history?
The Coherus Biosciences history is marked by significant achievements in the biosimilar market, including key FDA approvals and product launches, alongside strategic shifts to focus on oncology. The company's evolution reflects a dynamic approach to market opportunities and challenges.
| Year | Milestone |
|---|---|
| 2017 | FDA approval of UDENYCA. |
| 2019 | Launch of UDENYCA in the U.S. market. |
| 2022 | Launch of CIMERLI, the first and only FDA-approved interchangeable biosimilar to Lucentis. |
| 2023 | Launch of YUSIMRY, a Humira biosimilar, at a significant discount. |
| 2023 | Launch of the UDENYCA autoinjector. |
| 2024 | FDA approval and launch of UDENYCA OnBody. |
| March 2024 | Divestiture of the CIMERLI ophthalmology franchise. |
| April 2025 | Divestiture of the UDENYCA franchise. |
Coherus Biosciences has driven innovation through the development and launch of biosimilar products, aiming to increase patient access to affordable treatments. The introduction of an autoinjector and an on-body injector for UDENYCA provided patients with more convenient administration options.
UDENYCA Launch
The FDA approval of UDENYCA in 2017 and its subsequent launch in January 2019 marked Coherus' entry into the U.S. biosimilar market, transforming it into a commercial entity.
CIMERLI Interchangeability
The launch of CIMERLI in October 2022 as the first and only FDA-approved interchangeable biosimilar for all indications of Lucentis expanded the company's portfolio and market reach.
YUSIMRY Pricing Strategy
The introduction of YUSIMRY in July 2023, priced at over an 85% discount to the reference product, demonstrated a commitment to affordability and patient access.
UDENYCA Delivery Systems
The launch of the UDENYCA autoinjector in May 2023 and the FDA approval of UDENYCA OnBody in December 2023 offered enhanced patient convenience.
Oncology Focus with LOQTORZI
The strategic pivot towards oncology is highlighted by the advancement of LOQTORZI, an FDA-approved PD-1 inhibitor, which generated $7.3 million in net product sales in Q1 2025.
Pipeline Advancement
The company is advancing novel immuno-oncology candidates like CHS-114 and casdozokitug, with clinical data expected in 2026, indicating a focus on future growth areas.
Coherus Biosciences has navigated significant challenges, including intense market competition and pricing pressures within the biosimilar sector. These market dynamics led to strategic decisions, such as a 30% workforce reduction in 2023 and the divestiture of key franchises.
Market Competition
The biosimilar market is characterized by intense competition and significant pricing pressures, impacting revenue streams and requiring strategic adjustments.
Operational Streamlining
In response to market conditions, the company implemented a workforce reduction of 30% in 2023 to streamline operations and manage costs effectively.
Strategic Divestitures
The divestiture of the UDENYCA franchise in April 2025 for up to $558.4 million and the CIMERLI franchise in March 2024 represent a significant strategic pivot to focus exclusively on innovative oncology.
Financial Management
The company anticipates annualized savings of $25 million from headcount reductions and projects SG&A expenses between $90 million and $100 million for 2025, reflecting careful financial planning.
Focus on Oncology
The strategic transformation aims to maximize revenues from its innovative oncology portfolio, particularly LOQTORZI, and advance its pipeline of novel immuno-oncology candidates.
Market Share Dynamics
While CIMERLI captured a 25% market share of the ranibizumab market by August 2023, the overall biosimilar market requires continuous adaptation to maintain competitive positioning. Understanding the Competitors Landscape of Coherus Biosciences is crucial in this context.
Coherus Biosciences Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for Coherus Biosciences?
The Coherus Biosciences history showcases a dynamic journey from its founding in 2010 to its current strategic pivot towards innovative oncology. This Coherus Biosciences company profile highlights key milestones in its evolution, including significant product approvals, market launches, and strategic acquisitions that have shaped its trajectory.
| Year | Key Event |
|---|---|
| 2010 | Coherus BioSciences was founded by Dennis Lanfear in Redwood City, California. |
| 2011 | The company completed its Series A financing round, securing $55 million. |
| 2012 | Coherus filed its first biosimilar application in Europe. |
| 2014 | A global Phase 3 clinical trial was initiated for its lead biosimilar candidate. |
| 2017 | The U.S. FDA approved UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta. |
| 2019 | UDENYCA was launched in the U.S. market in January, and commercial rights for Bioeq's Lucentis biosimilar candidate in the U.S. were acquired in November. |
| 2020 | Commercial rights for Innovent's Avastin biosimilar were acquired in January, with an option for a Rituxan biosimilar. |
| 2022 | The FDA approved CIMERLI (ranibizumab-eqrn), an interchangeable biosimilar to Lucentis, in August, followed by its commercial launch in October. |
| 2023 | The UDENYCA autoinjector was launched in May, followed by the launch of YUSIMRY (adalimumab-aqvh), a Humira biosimilar, in July. The company also acquired Surface Oncology in September, expanding into the oncolytic space. |
| 2023 | FDA approved UDENYCA OnBody in December. |
| 2024 | UDENYCA OnBody was launched in February. |
| 2024 | The CIMERLI ophthalmology franchise was divested in March. |
| 2025 | The UDENYCA franchise was divested for up to $558.4 million in April, with a strategic focus on innovative oncology. |
Strategic Oncology Focus
Coherus is transforming into an oncology-focused company. This shift aims to maximize the value of its pipeline for extending cancer patient survival.
LOQTORZI Revenue Maximization
The company's future trajectory is centered on maximizing LOQTORZI revenues. Projected sales in nasopharyngeal carcinoma (NPC) are expected to reach $150 million to $200 million annually over the next three years.
Pipeline Advancement in Oncology
Coherus is advancing novel immuno-oncology candidates, CHS-114 and casdozokitug. Data readouts for ongoing Phase 1b studies in 2L HNSCC and 2L gastric cancer are anticipated in 2026.
Analyst Consensus and Price Targets
As of July 26, 2025, 15 analysts have issued a 'Buy' consensus rating for Coherus BioSciences, with an average price target of $20.27. Some forecasts suggest a potential 12-month upside of 433.26%, with an average stock forecast of $4.78.
Coherus Biosciences Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Competitive Landscape of Coherus Biosciences Company?
- What is Growth Strategy and Future Prospects of Coherus Biosciences Company?
- How Does Coherus Biosciences Company Work?
- What is Sales and Marketing Strategy of Coherus Biosciences Company?
- What are Mission Vision & Core Values of Coherus Biosciences Company?
- Who Owns Coherus Biosciences Company?
- What is Customer Demographics and Target Market of Coherus Biosciences Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.